CJC-1295 without DAC

CJC-1295 without DAC (Modified GRF 1-29) – Research Peptide
Class: Growth Hormone Releasing Hormone (GHRH) analog
Form: Lyophilized powder
Purity: ≥ 99% (HPLC verified)
Storage (dry): Room temperature, away from light
Storage (reconstituted): Refrigerate 2–8°C
Solvent compatibility: Bacteriostatic Water (preferred)
CJC-1295 without DAC (Drug Affinity Complex), also known as Modified GRF 1-29, is a synthetic analog of the naturally occurring growth hormone-releasing hormone. By modifying the first 29 amino acids of GHRH, researchers have developed a more stable compound for laboratory study. It is widely utilized in research settings to investigate pulsatile growth hormone secretion and its subsequent effects on cellular growth and metabolic signaling.
Key Research Focus Areas
Pulsatile GH Secretion: Investigation of the peptide’s ability to stimulate the anterior pituitary to release growth hormone in natural, episodic pulses.
Protein Synthesis & Muscle Hypertrophy: Study of the downstream effects on IGF-1 levels and their role in nitrogen retention and muscle tissue modeling.
Lipolysis & Metabolic Rate: Analysis of the peptide’s influence on adipose tissue breakdown and systemic lipid metabolism in research models.
Cellular Repair & Recovery: Researching the impact of enhanced GH signaling on the recovery of stressed or damaged musculoskeletal tissues.
Sleep Quality & Circadian Rhythm: Evaluation of the correlation between GHRH analogs and the regulation of deep-wave sleep cycles in pre-clinical settings.
Format Options

5 mg lyophilized powder
Optional BAC solvent available separately
Important Notice
All products are sold for laboratory research use only. Not for human consumption, injection, or diagnostic use.

CJC-1295 without DAC

Name: CJC-1295 without DAC
SKU: 654
Availability: InStock

Research Peptide

CJC-1295 without DAC is a synthetic growth hormone-releasing hormone (GHRH) analog designed to stimulate natural growth hormone release without the extended half-life provided by Drug Affinity Complex (DAC) technology. It has become an important focus of preclinical research involving growth hormone signaling, recovery, and metabolic regulation.

Potential Research Applications

Current preclinical and investigational research has explored CJC-1295 without DAC for its potential role in:

Mechanism of Action

Although research is ongoing, CJC-1295 without DAC has demonstrated activity through several biological pathways, including:

Stimulation of growth hormone-releasing hormone (GHRH) receptors
Promotion of pulsatile endogenous growth hormone release
Support of IGF-1 production and signaling
Modulation of protein synthesis and recovery pathways
Support of metabolic regulation in experimental models

These mechanisms have made CJC-1295 without DAC a significant area of interest in regenerative medicine and endocrine research.

Product Information

High-purity lyophilized research peptide
Manufactured under strict quality standards
Third-party tested for identity and purity
Intended exclusively for laboratory and scientific research applications

Research Disclaimer

This product is intended for laboratory research purposes only. It is not approved by the U.S. Food and Drug Administration (FDA) for human or veterinary use and is not intended to diagnose, treat, cure, or prevent any disease. It should only be handled by qualified professionals in appropriate research settings.